Lenti-WT1 TCR (TAK1)-VP(VP-TCR-C583)

The ready-to-use lentiviral particles of Lenti-WT1 TCR (TAK1)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

Type of Therapeutics

T cell receptor

Target

WT1

Clone

TAK1

Promotor

CMV

Packaging System

Lentivirus

Packaging Cell

293T

Targeting Diseases

Leukemia

Target

Introduction

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and aproline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normaldevelopment of the urogenital system, and it is mutated in a small subset of patients with Wilmstumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic,and monoallelic expression from the maternal and paternal alleles in different tissues. Multipletranscript variants have been described. In several variants, there is evidence for the use of a nonAUG(CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors ofPMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, andthat this process is tissue-restricted and developmentally regulated.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.